CN118488853A - 组合疗法 - Google Patents

组合疗法 Download PDF

Info

Publication number
CN118488853A
CN118488853A CN202280066217.5A CN202280066217A CN118488853A CN 118488853 A CN118488853 A CN 118488853A CN 202280066217 A CN202280066217 A CN 202280066217A CN 118488853 A CN118488853 A CN 118488853A
Authority
CN
China
Prior art keywords
dose
glp
agonist
actrii receptor
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280066217.5A
Other languages
English (en)
Chinese (zh)
Inventor
L·B·科立克斯泰恩
M·马查茨克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Visanis Biological Co
Original Assignee
Visanis Biological Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Visanis Biological Co filed Critical Visanis Biological Co
Publication of CN118488853A publication Critical patent/CN118488853A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280066217.5A 2021-08-27 2022-08-26 组合疗法 Pending CN118488853A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163238068P 2021-08-27 2021-08-27
US63/238,068 2021-08-27
US202263301012P 2022-01-19 2022-01-19
US63/301,012 2022-01-19
US202263333351P 2022-04-21 2022-04-21
US63/333,351 2022-04-21
PCT/US2022/075545 WO2023028606A1 (en) 2021-08-27 2022-08-26 Combination therapies

Publications (1)

Publication Number Publication Date
CN118488853A true CN118488853A (zh) 2024-08-13

Family

ID=83897998

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280066217.5A Pending CN118488853A (zh) 2021-08-27 2022-08-26 组合疗法

Country Status (11)

Country Link
US (1) US20240325530A1 (cg-RX-API-DMAC7.html)
EP (1) EP4392137A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024532619A (cg-RX-API-DMAC7.html)
KR (1) KR20240099142A (cg-RX-API-DMAC7.html)
CN (1) CN118488853A (cg-RX-API-DMAC7.html)
AU (1) AU2022332306A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229355A1 (cg-RX-API-DMAC7.html)
IL (1) IL310919A (cg-RX-API-DMAC7.html)
MX (1) MX2024002467A (cg-RX-API-DMAC7.html)
TW (1) TW202323296A (cg-RX-API-DMAC7.html)
WO (1) WO2023028606A1 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4121078A4 (en) 2020-03-20 2024-08-14 Keros Therapeutics, Inc. ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF
EP4121088A4 (en) 2020-03-20 2024-07-03 Keros Therapeutics, Inc. Methods of using activin receptor type iib variants
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
EP4466288A4 (en) * 2022-01-19 2026-02-25 Versanis Bio Inc ACTRII ANTIBODY-BASED TREATMENTS
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
EP4577301A1 (en) 2022-08-26 2025-07-02 Versanis Bio, Inc. Actrii antibody fixed unit dose treatments
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
IL326224A (en) 2023-07-31 2026-03-01 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2025106773A1 (en) * 2023-11-17 2025-05-22 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea with a combination of a glp-1 agonist and a second active agent
IL330385A (en) * 2023-12-29 2026-08-01 Jiangsu Hengrui Pharmaceuticals Co Ltd Antibody-polypeptide conjugate and its pharmaceutical use
WO2025147483A1 (en) * 2024-01-02 2025-07-10 Keros Therapeutics, Inc. Methods of using activin receptor type ii chimeras
WO2025183966A1 (en) 2024-02-28 2025-09-04 Versanis Bio, Inc. Actrii antibodies with extended half life
WO2025217521A1 (en) * 2024-04-12 2025-10-16 Jnana Therapeutics Inc. Treating chronic kidney disease with a combination of a slc6a19 inhibitor and a glp-1 agonist
WO2025247309A1 (zh) * 2024-05-31 2025-12-04 上海齐鲁制药研究中心有限公司 融合蛋白分子及其应用
WO2026128614A1 (en) * 2024-12-10 2026-06-18 Supercede Therapeutics, Inc. Activin receptor type ii inhibitors for preventing or treating obesity and related disorders
EP4785960A1 (en) 2025-01-31 2026-08-05 SixPeaks Bio AG Glp-1 antibody conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2655877T3 (es) 2009-04-27 2018-02-22 Novartis Ag Composiciones y métodos para aumentar el crecimiento muscular
JOP20190152A1 (ar) 2016-12-21 2019-06-20 Novartis Ag مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة
WO2018129395A1 (en) * 2017-01-06 2018-07-12 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation

Also Published As

Publication number Publication date
US20240325530A1 (en) 2024-10-03
MX2024002467A (es) 2024-05-20
EP4392137A1 (en) 2024-07-03
WO2023028606A1 (en) 2023-03-02
AU2022332306A1 (en) 2024-02-29
CA3229355A1 (en) 2023-03-02
IL310919A (en) 2024-04-01
TW202323296A (zh) 2023-06-16
KR20240099142A (ko) 2024-06-28
JP2024532619A (ja) 2024-09-05

Similar Documents

Publication Publication Date Title
US20240325530A1 (en) Combination therapies
JP2024532619A5 (cg-RX-API-DMAC7.html)
CN120815164A (zh) 使用gip/glp1共激动剂用于治疗的方法
JP2024521091A (ja) 褐色脂肪生成を誘導する方法及び組成物
AU2020341135A1 (en) Treatment of liver disease or disorder comprising ActRII receptor antagonists
JP2023515771A (ja) 強皮症および関連する疾病の処置のための方法
JP2008518941A (ja) 大腸連続性を伴う短腸症候群患者の治療
US20260070992A1 (en) Actrii antibody fixed unit dose treatments
CN118055767A (zh) 新颖的组合施用
EP2240195A1 (en) Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
JP2025504453A (ja) ActRII抗体治療
JP2023510609A (ja) Glp-1および/またはglp-1類似体、ならびにインスリンおよび/またはインスリン類似体を含む併用療法
WO2023056297A1 (en) Cd40l-specific tn3-derived scaffolds for the treatment and prevention of sjogren's syndrome
KR20260013453A (ko) 체중 관련 동반질환이 있거나 없는 과체중 또는 비만 성인의 치료
WO2025183966A1 (en) Actrii antibodies with extended half life
JP2023518645A (ja) Glp-1の投薬レジメン
RU2838150C1 (ru) Лечение заболевания или нарушения со стороны печени, предусматривающее применение антагонистов рецепторов actrii
US20230331859A1 (en) Methods for treating short bowel syndrome and/or high output ostomy
CN121969358A (zh) 选择性雄激素受体调节剂(sarm)化合物在长期体重管理中的用途
WO2025245160A1 (en) Myostatin-selective inhibitors for treating metabolic disorders
CN118201629A (zh) 用于治疗和预防干燥综合征的cd40l特异性tn3衍生的支架
Fukuda et al. OR07-2 METABOLIC COMPLICATIONS REVEALED IN 42 PATIENTS WITH CHILDHOOD-ONSET ADULT GH DEFICIENCY AFTER THE CESSATION OF GH REPLACEMENT THERAPY FOR SHORT STATURE
Cohen et al. OR07-3 VALIDATION OF THE EFFICACY AND SAFETY OF IGF-BASED DOSE-TITRATION IN CHILDREN WITH GROWTH FAILURE ASSOCIATED WITH NON-GH-DEFICIENT, IGF-I DEFICIENCY: RESULTS OF CLINICAL TRIAL HGH 2147 ON BEHALF OF THE AMERICAN Norditropin® CLINICAL STUDIES GROUP
Miyasaka Etanercept and methotrexate for the treatment of rheumatoid arthritis
Smyth et al. trials tell us?[version 1; peer review: 2 approved]

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination